Abivax SA reports developments as a clinical-stage biotechnology company developing therapeutics that modulate immune response in chronic inflammatory diseases. Its news centers on obefazimod (ABX464), the company’s lead therapeutic candidate, including clinical and preclinical data in inflammatory bowel disease, Phase 3 ABTECT work in moderately to severely active ulcerative colitis, and related safety, efficacy, biomarker, and patient-reported outcome analyses.
Recurring updates also cover financial results, annual and regulatory reporting in France and the United States, American Depositary Share offerings, royalty certificate obligations, public-company governance, annual meeting materials, and trading references for its Euronext Paris and Nasdaq-listed securities.
Abivax (ABVX) will present seven obefazimod abstracts at United European Gastroenterology Week, taking place October 17–20, 2026, in Barcelona, Spain.
The program includes four oral presentations and three posters covering Phase 3 ABTECT Maintenance and Induction trials in moderately to severely active ulcerative colitis, long-term Phase 2 follow-up, and preclinical research on inflammation, fibrosis and tumor activity. Clinical presentations include the 44-week maintenance trial and three-year interim analyses following dose reduction to 25 mg in the Phase 2 program. Presentations will be available on Abivax’s publications webpage after the meeting concludes.
Abivax (ABVX) reported first half 2026 results and business updates, highlighting major financing, cash runway extension and leadership changes as it advances obefazimod toward potential commercialization.
Cash, cash equivalents and short-term investments were €402.4 million at June 30, 2026. Together with €767.1 million in net proceeds from a July underwritten ADS offering, the company projects a cash runway into Q4 2029 based on current assumptions. In May, Abivax repurchased and cancelled all outstanding royalty certificates for about $90 million (€76.5 million), including 403,347 new shares, eliminating the royalty liability and supporting a debt‑light balance sheet.
R&D expenses rose to €107.9 million, G&A to €30.4 million, and sales and marketing to €4.6 million, driving an operating loss of €140.3 million and a net loss of €165.9 million for the period. Chris Rabbat will succeed Fabio Cataldi as Chief Medical Officer and Tim Kelly has been appointed Chief Technical Officer, both effective immediately.
Abivax (Euronext Paris & Nasdaq: ABVX) reported a positive pre-New Drug Application (NDA) interaction with the U.S. FDA for its lead candidate obefazimod in adults with moderately to severely active ulcerative colitis. The FDA provided constructive feedback and aligned with Abivax on its planned NDA submission strategy, including the content and format of the filing.
According to Abivax, the company remains on track to submit its first NDA for obefazimod by the end of 2026. Management highlighted that this regulatory milestone builds on previously announced positive Phase 3 ABTECT program results in ulcerative colitis, which continue to underpin obefazimod’s potential in this indication.
Abivax (Euronext Paris/Nasdaq: ABVX) expanded its Commercial Leadership Team with four senior appointments across marketing, patient services, sales/commercial operations, and market access/pricing. The company stated these roles are intended to support the potential U.S. commercialization of its lead candidate obefazimod, ahead of a planned NDA submission to the FDA in Q4 2026.
James Berger becomes Global Head of Marketing, leading commercial strategy and brand development for obefazimod. Ivan Nuñez-Pacheco is appointed Global Head of Patient Services, overseeing the global patient services model. Heather Dean assumes the role of Global Head of Sales, Accounts & Commercial Operations, while Jeff Haas becomes Global Head of Market Access & Pricing, responsible for market access and pricing strategies.
Abivax (NASDAQ:ABVX) closed its underwritten public offering of 7,360,000 ADSs in the US, including full exercise of the underwriters’ option. The Offering generated gross proceeds of about $920.0 million and estimated net proceeds of about $874.1 million.
According to Abivax, combining these funds with existing cash is expected to finance operations into Q4 2029. The company’s ordinary shares trade on Euronext Paris and its ADSs on Nasdaq, both under the symbol ABVX.
Abivax (Nasdaq:Euronext: ABVX) announced that underwriters fully exercised their option to buy 960,000 additional ADSs, bringing the total Offering to 7,360,000 ADSs.
This increases gross proceeds to about $920.0M (€807.4M) and estimated net proceeds to about $874.1M (€767.1M), mainly to fund obefazimod commercialization and inflammatory bowel disease R&D.
Abivax (Nasdaq: ABVX) priced an upsized underwritten public offering of 6,400,000 ADSs at $125.00 per ADS, raising expected gross proceeds of about $800M (€702M), with a 15% underwriters’ option. The deal is priced at a 2.39% premium and is expected to extend the cash runway into Q2 2029, funding potential commercialization of obefazimod and continued clinical development.
Abivax (Euronext Paris: ABVX) announced that trading of its ordinary shares on Euronext Paris will resume on July 1, 2026 at 3:30 p.m. CEST.
Trading was halted at the Company’s request from 9:00 a.m. CEST in connection with allocation confirmation and pricing of its US ADS public offering.
Abivax (Nasdaq: ABVX) priced an oversubscribed, upsized underwritten public offering of 6,400,000 ADSs at $125.00 per ADS, raising expected gross proceeds of about $800M (€702M), excluding any underwriters’ option exercise.
Net proceeds and existing cash are expected to fund operations, including potential obefazimod commercialization and clinical development, into Q2 2029. Dilution is estimated at 8.0–9.2%, depending on full exercise of the 960,000 ADS underwriters’ option.
Abivax (ABVX), a clinical-stage biotechnology company, requested a temporary halt of trading in its ordinary shares on Euronext Paris from 9:00 a.m. CEST on July 1, 2026. The halt supports confirming allocations and announcing pricing for a previously announced ADS public offering in the United States. Trading is expected to resume around 3:30 p.m. CEST the same day.